Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.81 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.81 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 3/20 | 0.65 |
| ▸ | IGF1R | P08069 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | INSR | P06213 | 2/20 | 0.61 |
| ▸ | CDC7 | O00311 | 1/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.61 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | PAK4 | O96013 | 1/20 | 0.61 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19027876 | 0.94 | ALK (0.72) | EGFRALKMAP4K1METIGF1R | |
| SCHEMBL19027783 | 0.94 | ALK (0.72) | EGFRALKMAP4K1METIGF1R | |
| SCHEMBL19027772 | 0.93 | ALK (0.71) | EGFRALKMAP4K1METIGF1R | |
| SCHEMBL16371046 | 0.93 | EGFR (0.83) | EGFRALKMAP4K1METIGF1R | |
| SCHEMBL19027770 | 0.92 | EGFR (0.70) | EGFRALKMAP4K1METIGF1R | |
| SCHEMBL19027866 | 0.92 | EGFR (0.70) | EGFRALKMAP4K1METIGF1R | |
| SCHEMBL19027551 | 0.91 | ALK (0.67) | EGFRALKMAP4K1METIGF1R | |
| SCHEMBL16370785 | 0.90 | EGFR (1.00) | EGFRALKIGF1RKCNH2INSR | |
| SCHEMBL21164794 | 0.89 | EGFR (0.77) | EGFRALKIGF1RKCNH2JAK2 | |
| SCHEMBL14150200 | 0.89 | ALK (0.74) | EGFRALKMAP4K1IGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20180369242-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2018-12-27 | — | — | US | disclosed |
| EP-3392245-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017101803-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | 合肥中科普瑞昇生物医药科技有限公司 | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369242-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | ALK, EGFR, NPM1 | EGFR 2/4885ALK 1/4885MAP4K1 2143/4885 |
| US-10350210-B2 | EGFR and ALK dual inhibitor | ALK, EGFR, ERBB2 | EGFR 2/4885ALK 1/4885MAP4K1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.